Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954

European Journal of Cancer

Volumn 31, Issue 13-14, 1995, Pages 2362-2370

  Bridgewater, J A ^a   Springer, C J ^a   Knox, R J ^a   Minton, N P ^b   Michael, N P ^b   Collins, M K ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

Author keywords

CB1954; ganciclovir; GDEPT; gene therapy; Herpes simplex thymidine kinase; nitroreductase; prodrugs; VDEPT

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; GANCICLOVIR; NITROREDUCTASE; PRODRUG; THYMIDINE KINASE; VIRUS VECTOR;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; GENE THERAPY; GENE TRANSFER; HERPES VIRUS; HUMAN; HUMAN CELL; MELANOMA; MESOTHELIOMA; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; RETROVIRUS;

3T3 CELLS; ANIMALS; AZIRIDINES; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; GANCICLOVIR; GENE TRANSFER TECHNIQUES; GENES, BACTERIAL; GENES, VIRAL; HUMANS; MICE; NITROREDUCTASES; PRODRUGS; THYMIDINE KINASE; VIRAL STRUCTURAL PROTEINS;

EID: 0029609610     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00436-X     Document Type: Article

References (37)

1. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy
2. Inhibition of cellular DNA polymerase-alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl) guanine
3. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors
4. Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: an innovative approach for cancer therapy
5. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene
6. Use of recombinant adenovirus to transfer the herpes simplex virus thymidine kinase (HSVtk) gene to thoracic neoplasms: an effective in vitro drug sensitization system
7. Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA
8. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats
9. Gene therapy for the treatment of brain tumors using intra-tumoral transduction with the thymidine kinase gene and intravenous ganciclovir
10. Tumour growth inhibitory nitrophenylaziridines and related compounds structure activity relationships
11. The therapeutic response of three human lines maintained in immune suppressed mice
12. The nitroreductase enzyme in Walker cells that activates 5-(aziridinl-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2)
13. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—II. A comparison of an Escherichia coli nitroreductase and Walker DT diaphorase
14. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)2, 4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells
15. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of cell lines to CB1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide]
16. The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB1954)—I. Purification and properties of a nitroreductase enzyme from Escherichia coli—a potential enzyme for antibody-directed enzyme prodrug therapy (ADEPT)
17. Physical characterisation of the Escherichia coli B gene encoding nitroreductase and its over-expression in Escherichia coli K12
18. Point mutations define a sequence flanking the aug initiator codon that modulates translation by eukaryotic ribosomes
19. Isolation of monoclonal antibodies specific for human c-myc proto-oncogene product
20. Construction and use of a safe and efficient amphotropic packaging cell line
21. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promotor
22. Characterisation of human ovarian carcinoma cell line (NIH: OVCAR-3) with androgen and oestrogen receptors
23. Generation of interleukin-2 secreting melanoma cell populations from resected metastatic tumours
24. Characterization of a human malignant mesothelioma cell line (H-MESO-1): a biphasic solid and ascitic tumor model
25. Making high titre retoviral producer cells
26. Cleavage of structural proteins during the assembly of the head of bacteriphage T4
27. An improved MTT assay using the electron-coupling agent menadione
28. New colorimetric cytotoxicity assay for anticancer-drug screening
29. Retroviral-mediated gene transfer into hepatocytes in vivo
30. The nucleotide sequence and transcript map of the herpes simplex virus thymidine kinase gene
31. CB 1954 revisited: I. Disposition kinetics and metabolism
32. CB1954 (2,4-dinitro-5-aziridinyl benzamide) becomes a DNA interstrand crosslinking agent in Walker tumour cells
33. Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines
34. The growth fraction: a new concept applied to tumours
35. The “bystander effect”: tumor regression when a fraction of the tumor mass is genetically modified
36. Intrathecal gene therapy for malignant leptomeningeal neoplasia
37. In vivo combination gene therapy with the herpes simplex thymidine kinase (HS-tk) and interleukin-2 (IL-2) genes for the treatment of ovarian cancer